KRM Ayurveda Ltd · KRMAYURVED · Hospitals/Medical Services · price as of the 20 November 2026 close, updated every trading day · results updated weekly · research updated 5 May 2026
KRM Ayurveda share price today: ₹220.35 at the close on 20 November 2026. KRM Ayurveda (KRMAYURVED) is worth ₹469 crore and trades at a P/E of 23.3. Latest change: operating margin up 12 points on a year earlier.
KRM Ayurveda Ltd's results are improving, while its P/E is near the low end of its own history over 10 months, higher than only 0% of past readings.
The main question: profits are rising, but only 9% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch.
The price is in an uptrend that has just slipped below its 200-day average, and the P/E is lower than 100% of its own last 10 months. Over the last four quarters, results have been improving, with profit +124.2% on a year earlier, and 9% of the last 3 years' profit came in as cash. What will decide it: whether the cash starts to follow the profit.
Figures we could not check: Some figures on this page come from a second data source that we could not check against the main one, because the two do not cover enough of the same periods. They are shown because they are the only figures there are, and every section that uses one is marked unverified.
What is the KRM Ayurveda share price today?
KRM Ayurveda Ltd's share price was ₹220.35 at the close on 20 November 2026. It is in an uptrend that has just slipped below its 200-day average. That is 10.6% below its average price over the last 200 trading days.
A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today KRM Ayurveda Ltd is in stage 2. The phase helps read everything below.
Since its first close in our records, on 1 February 2026, it has traded between ₹161 and ₹330, and at that close it sat 35% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 5 weeks running.
Week by week since 2026: did it beat the NIFTY 500 over the past 13 weeks?
Ahead in 29 of 37 weeks
| Week | 13-week return vs NIFTY 500 |
|---|---|
| 1 Feb 2026 | no NIFTY 500 reading |
| 6 Feb 2026 | no NIFTY 500 reading |
| 13 Feb 2026 | no NIFTY 500 reading |
| 20 Feb 2026 | no NIFTY 500 reading |
| 27 Feb 2026 | no NIFTY 500 reading |
| 6 Mar 2026 | no NIFTY 500 reading |
| 13 Mar 2026 | no NIFTY 500 reading |
| 20 Mar 2026 | no NIFTY 500 reading |
| 27 Mar 2026 | no NIFTY 500 reading |
| 2 Apr 2026 | no NIFTY 500 reading |
| 10 Apr 2026 | no NIFTY 500 reading |
| 17 Apr 2026 | no NIFTY 500 reading |
| 24 Apr 2026 | no NIFTY 500 reading |
| 30 Apr 2026 | +41.7% |
| 8 May 2026 | +49.1% |
| 15 May 2026 | +12.2% |
| 22 May 2026 | +17.5% |
| 29 May 2026 | +31.4% |
| 4 Jun 2026 | +24.5% |
| 5 Jun 2026 | +20.7% |
| 9 Jun 2026 | +12.1% |
| 10 Jun 2026 | +15.5% |
| 12 Jun 2026 | +21.0% |
| 17 Jun 2026 | +20.3% |
| 19 Jun 2026 | −1.8% |
| 24 Jun 2026 | +16.5% |
| 25 Jun 2026 | +8.9% |
| 1 Jul 2026 | −2.5% |
| 3 Jul 2026 | +1.0% |
| 10 Jul 2026 | +3.3% |
| 17 Jul 2026 | −11.4% |
| 24 Jul 2026 | +0.6% |
| 31 Jul 2026 | +10.4% |
| 7 Aug 2026 | +25.2% |
| 14 Aug 2026 | +19.7% |
| 21 Aug 2026 | +9.6% |
| 28 Aug 2026 | +10.4% |
| 4 Sep 2026 | +21.0% |
| 11 Sep 2026 | +16.9% |
| 18 Sep 2026 | +20.3% |
| 25 Sep 2026 | +19.4% |
| 28 Sep 2026 | +20.2% |
| 1 Oct 2026 | +16.2% |
| 9 Oct 2026 | +20.6% |
| 16 Oct 2026 | +5.2% |
| 23 Oct 2026 | −4.5% |
| 30 Oct 2026 | −17.7% |
| 8 Nov 2026 | −17.7% |
| 13 Nov 2026 | −17.9% |
| 20 Nov 2026 | −22.2% |
Over the last 10 months the share price moved +30% while the NIFTY 500 moved +3%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 16 October 2026. The chart above shows the 13-week comparison for every week.
This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.
What changed at KRM Ayurveda this quarter?
One change stood out: operating margin up 12 points on a year earlier.
Operating margin up 12 points on a year earlier
37.2% in the June 2026 quarter, from 25.2%.
What are KRM Ayurveda's latest quarterly results?
For April to June 2026 (the quarter ended 30 June 2026), KRM Ayurveda reported revenue of ₹32.3 crore, up 31.0% from ₹24.7 crore a year earlier, and a profit of ₹9.08 crore, up 124.2% from ₹4.05 crore.
KRM Ayurveda results: April to June 2026 against a year earlier
| Measure | April to June 2026 | April to June 2025 | Change |
|---|---|---|---|
| Revenue | ₹32.3 crore | ₹24.7 crore | +31.0% |
| Profit | ₹9.08 crore | ₹4.05 crore | +124.2% |
| Earnings per share | ₹4.27 | ₹2.70 | +58.1% |
| Operating margin | 37.2% | 25.2% | +12.0 points |
The next results, for July to September 2026, were due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). This page shows them once our weekly data update has read them.
The newest call in our records is from 5 May 2026, about January to March 2026; a call about these results is not in our records yet.
From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.
What is the KRM Ayurveda share price history?
KRM Ayurveda closed at ₹220.35 on 20 November 2026. Its highest weekly close since February 2026 was ₹312.20 on 18 September 2026.
KRM Ayurveda share price: then and now
| When | Close | Change to 20 Nov 2026 |
|---|---|---|
| 1 week ago · 13 Nov 2026 | ₹229.90 | −4.2% |
| 1 month ago · 19 Oct 2026 | ₹246.60 | −10.6% |
| 6 months ago · 22 May 2026 | ₹243.40 | −9.5% |
| Earliest and lowest weekly close in our records · 1 Feb 2026 | ₹168.95 | +30.4% |
| Highest weekly close since February 2026 · 18 Sep 2026 | ₹312.20 | −29.4% |
Weekly closing prices. Each change is the move from that price to the 20 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.
50 weekly closes from 1 February 2026 to 20 November 2026.
What is the latest news on KRM Ayurveda?
20 Nov 2026: KRM Ayurveda closed at ₹220.35, down 4.2% on the week and down 10.6% on the month. Results for April to June 2026: Revenue up 31.0% and profit up 124.2% on a year earlier.
Earlier
- 5 May 2026: KRM Ayurveda held its results call for January to March 2026.
What dividend does KRM Ayurveda pay?
KRM Ayurveda has paid no dividend on the exchange since its first close in our records (1 February 2026), the start of the period we checked.
No. KRM Ayurveda Ltd paid out 0% of its profit as dividends in each of its last 4 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.
From the exchange corporate-actions record, read 20 November 2026.
What to watch in KRM Ayurveda's next results?
When KRM Ayurveda reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Revenue against the same quarter a year earlier.
- Revenue against the same quarter a year earlier. In the Jun 2026 quarter, revenue was +31.0% on a year earlier, and the last four quarters averaged +4.8%.
- Whether the operating margin stays near 37.2%. It is 17.7 percentage points higher than four quarters earlier.
- Net profit against the same quarter a year earlier. In the Jun 2026 quarter, profit was +124.2% on a year earlier. It has grown on a year earlier for 2 quarters in a row.
- Whether cash from operations catches up with profit. Only 9% of the last 3 years' profit came in as cash from operations.
Which stock lists is KRM Ayurveda on?
KRM Ayurveda is not on any of our India lists this week.
Is KRM Ayurveda profitable?
KRM Ayurveda Ltd earned ₹9.1 Cr of net profit in the Jun 2026 quarter, +124.2% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹20.0 Cr. Over 3 years profit has grown 35.7% a year on average. The same quarter a year earlier earned ₹5.0 Cr.
Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.
The Jun 2026 quarter's profit is 28.1% of that quarter's revenue.
For the full year, FY26 profit was ₹20.0 Cr (+81.8% on the year before).
How much revenue does KRM Ayurveda make, and is it growing?
KRM Ayurveda Ltd reported ₹32.3 Cr of revenue in the Jun 2026 quarter, +31.0% on the same quarter a year earlier. Over 3 years it has grown 4.6% a year on average. The last full year, FY26, came in at ₹102 Cr.
Revenue is everything the company billed its customers in the period.
FY26 revenue was ₹102 Cr, +32.5% on the year before.
Recent pace: the last four quarters grew +4.8% on average, against 4.6% a year over the longer run, so this year is growing at about the same pace as its own long-run rate.
How much of every ₹100 of sales does KRM Ayurveda keep?
KRM Ayurveda Ltd's operating margin was 37.2% in the Jun 2026 quarter, 12.0 percentage points higher than the same quarter a year ago. Over the last four quarters it has moved +17.7 percentage points. Across 4 years it has been between 11.9% and 29.4%. The latest quarter is above every full year in that period.
Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.
Why the margin moved: operating margin changed +16.5 percentage points on the year while gross margin changed +5.4 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.
Is KRM Ayurveda's profit turning into cash?
Over the last 3 years, 9% of KRM Ayurveda Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹1.0 Cr of operating cash against ₹20.0 Cr of profit. After ₹1.0 Cr of spending on assets, ₹0.0 Cr was left over as free cash.
The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.
Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.
Why 9% of profit came in as cash: the cash cycle got 282 days longer between FY23 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.
What to look at next: less of the profit turns into cash than it should, and the cash cycle is 282 days longer. The next section looks at where the cash is stuck.
Where does KRM Ayurveda's cash go?
KRM Ayurveda Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 227 days in FY26, up from −55 days in FY23. It spent ₹7.0 Cr on assets over the last 3 years. Customers take 82 days to pay, and stock sits for 225 days on average.
Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.
At FY26 sales of ₹102 Cr, each day of that cycle ties up about ₹0.3 Cr, so roughly ₹63.0 Cr is tied up in the business at any time.
FY26: customers took 82 days to pay and stock sat for 225 days, about 7.4 months of sales sitting as stock, for a full cycle of 227 days, longer than FY23's −55.
The full loop: cash goes out to suppliers and production on day 0. Stock sits for 225 days. Customers pay about 82 days after that. Suppliers are paid at 80 days. Together that makes the 227-day cycle.
Spending on assets: ₹7.0 Cr over the last 3 years, against ₹3.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet.
In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.
What is KRM Ayurveda's P/E ratio, and how does it compare with its own history?
KRM Ayurveda Ltd's P/E is 23.3×, about the lowest it has ever been. Its usual P/E (the middle reading) is 30.2×, over 10 months of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.
P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.
In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.
Is the KRM Ayurveda business getting better or worse?
KRM Ayurveda Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend.
Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.
Why it matters: with too little history, we say so rather than guess a direction.
One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.
The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.
There are fewer than eight usable quarters, so this page does not guess a direction from so little history.
Compound annual growth rate (%)
Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.
| Measure | 1yr | 3yr | 5yr | 10yr |
|---|---|---|---|---|
| Revenue | +32.5% | +4.6% | — | — |
| Profit | +81.8% | +35.7% | — | — |
| EPS | +26.6% | +35.5% | — | — |
How much does KRM Ayurveda earn on its capital?
KRM Ayurveda Ltd earned a ROCE of 35% in FY26. That is up from a low of 22% in FY24. Its return on capital used (ROIC) is 13.1 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 19.6% net margin and 0.84× asset turnover (sales divided by assets).
Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.
Not checked: some figures in this section come from a second data source we could not check against the main one, because the two do not cover enough of the same periods. Where both report a period, the main source’s figure is shown.
Why the return is what it is (FY26): a 19.6% net margin × 0.84× asset turnover × 1.07× leverage (assets divided by equity) ≈ 17.6% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.
The key test, return on capital used minus the cost of capital: 25.1% − 12.0% = +13.1 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.
The 25.1% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 28.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.
Does KRM Ayurveda have too much debt?
KRM Ayurveda Ltd had ₹0.0 Cr of borrowings against ₹114 Cr of equity in FY26, so its debt is 0.00× its equity. Its operating profit is 10 times its interest bill. Over 3 years borrowings went from ₹20.0 Cr to ₹0.0 Cr. Over the last 3 of those years it spent ₹7.0 Cr on assets.
Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.
The spending on assets is being paid for from cash, not new debt.
What is the KRM Ayurveda shareholding pattern?
No group of KRM Ayurveda Ltd's owners changed its stake by a full percentage point over the last 2 quarters. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.
Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.
How far is KRM Ayurveda from balance-sheet trouble?
For KRM Ayurveda Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.
The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.
How does KRM Ayurveda rank in its industry?
64.4 out of 100, rank 6 of 8 in Hospitals/Medical Services, with 38% of the evidence available. It is provisional, so it is ranked below companies with full evidence.
KRM Ayurveda Ltd scores 64.4 out of 100 against the 8 companies it is compared with in Hospitals/Medical Services, ranking 6. Some evidence is missing, so the score is pulled toward the middle on purpose.
The three scored parts add up to the total exactly: 23.5 + 26.5 + 14.4 = 64.4 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here.
What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.
Which companies is KRM Ayurveda compared with?
KRM Ayurveda ranks 6 of 8 Hospitals/Medical Services companies on the 4-Factor Sector Score, with 64.4 out of 100.
- 1Dr Agarwals Health Care LtdAGARWALEYE · turning · Evidence leans up · 60% evidence58.9out of 100
How the score adds up
Growth & earnings 28.6/35 · Revenue 25.9% · Profit 42.1% · Operating margin change 0 points · 95% evidenceCapital efficiency 9.3/25 · ROCE 10.9% (year to Mar 2026) · Operating margin 26.9% · 76% evidenceValuation 8.5/20 · P/E 97.4× · PEG — · 15% evidenceRelative strength 12.5/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 11.5% · 1 year 12.1% · 25% evidence · 9 of 12 weeks aheadExact sum: 28.6 + 9.3 + 8.5 + 12.5 = 58.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 2Gujarat Kidney & Super Speciality LtdGKSL · breaking out · Evidence leans up · 63% evidence50.5out of 100
How the score adds up
Growth & earnings 23.8/43.75 · Revenue 100% · Profit 68.2% · Operating margin change -12.8 points · 100% evidenceCapital efficiency 15.5/31.25 · ROCE 14.5% (year to Mar 2026) · Operating margin 26.8% · 100% evidenceValuation 11.2/25 · P/E 61.9× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 23.8 + 15.5 + 11.2 = 50.5 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. - 3Park Medi World LtdPARKHOSPS · quiet · Too little evidence to rank firmly · 55% evidence48.5out of 100
How the score adds up
Growth & earnings 19.0/43.75 · Revenue 22.9% · Profit 12.3% · Operating margin change -7 points · 95% evidenceCapital efficiency 17.3/31.25 · ROCE 19.5% (year to Mar 2026) · Operating margin 20% · 76% evidenceValuation 12.2/25 · P/E 40.1× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 19 + 17.3 + 12.2 = 48.5 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. - 4Gaudium IVF and Women Health LtdGAUDIUMIVF · quiet · Evidence leans down · 63% evidence46.1out of 100
How the score adds up
Growth & earnings 9.5/43.75 · Revenue 22.9% · Profit 3.9% · Operating margin change -7.4 points · 100% evidenceCapital efficiency 22.8/31.25 · ROCE 29.5% (year to Mar 2026) · Operating margin 36% · 100% evidenceValuation 13.8/25 · P/E 30.4× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 9.5 + 22.8 + 13.8 = 46.1 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. - 5Nephrocare Health Services LtdNEPHROPLUS · quiet · Evidence leans down · 64% evidence44.4out of 100
How the score adds up
Growth & earnings 19.2/43.75 · Revenue 24.8% · Profit 100% · Operating margin change -5 points · 74% evidenceCapital efficiency 10.5/31.25 · ROCE 15.3% (year to Mar 2026) · Operating margin 20.8% · 100% evidenceValuation 14.7/25 · P/E 51.4× · PEG 1.22 · 65% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 19.2 + 10.5 + 14.7 = 44.4 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. - 6KRM Ayurveda Ltd this pageKRMAYURVED · Too little evidence to rank firmly · 38% evidence64.4out of 100
How the score adds up
Growth & earnings 23.5/43.75 · Revenue — · Profit — · Operating margin change 12 points · 32% evidenceCapital efficiency 26.5/31.25 · ROCE 35.3% (year to Mar 2026) · Operating margin 37.2% · 95% evidenceValuation 14.4/25 · P/E 23.3× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 23.5 + 26.5 + 14.4 = 64.4 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. - 7Unihealth Hospitals LtdUNIHEALTH · quiet · Too little evidence to rank firmly · 42% evidence53.5out of 100
How the score adds up
Growth & earnings 17.7/35 · Revenue — · Profit — · Operating margin change -4 points · 15% evidenceCapital efficiency 16.7/25 · ROCE 24.5% (year to Mar 2026) · Operating margin 33.9% · 57% evidenceValuation 10.2/20 · P/E 32.9× · PEG — · 15% evidenceRelative strength 8.9/20 · Strength vs its industry (price vs its 52-week average, weekly) -0.7% · Strength vs NIFTY 500 (same reading) 6.3% · 1 year 53.1% · 100% evidence · 5 of 12 weeks aheadExact sum: 17.7 + 16.7 + 10.2 + 8.9 = 53.5 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. - 8Credent Connect N Care LtdCREDENT · Too little evidence to rank firmly · 38% evidence50.5out of 100
How the score adds up
Growth & earnings 21.0/43.75 · Revenue — · Profit — · Operating margin change 0 points · 32% evidenceCapital efficiency 16.2/31.25 · ROCE 21.5% (quarter to Sep 2026) · Operating margin 13% · 95% evidenceValuation 13.3/25 · P/E 32.3× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 21 + 16.2 + 13.3 = 50.5 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.
In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.
Related companies: Hospitals/Medical Services, all 8 compared on one page.
Which companies are close to KRM Ayurveda in size?
KRM Ayurveda is the 7th largest of 7 Hospitals/Medical Services companies on Sector Alpha by market value (at the 20 November 2026 close). Just above it: Dr Agarwals Health Care, Park Medi World, Nephrocare Health Services, Gujarat Kidney & Super Speciality, Unihealth Hospitals and Gaudium IVF and Women Health. It is the smallest.
Hospitals/Medical Services companies close in size
- Dr Agarwals Health Care Ltd ₹17,545 crore
- Park Medi World Ltd ₹10,275 crore
- Nephrocare Health Services Ltd ₹6,595 crore
- Gujarat Kidney & Super Speciality Ltd ₹1,177 crore
- Unihealth Hospitals Ltd ₹844 crore
- Gaudium IVF and Women Health Ltd ₹725 crore
- KRM Ayurveda Ltd ₹468 crore
All 7 Hospitals/Medical Services companies, largest first
Companies close in size in other industries
- Nisus Finance Services Co Ltd ₹472 crore
- Integra Engineering India Ltd ₹469 crore · Capital Goods - Engineering Heavy
- KRM Ayurveda Ltd ₹468 crore
- Oswal Agro Mills Ltd ₹467 crore · Trading
- Blue Pearl Agriventures Ltd ₹466 crore · Trading
What else do people ask about KRM Ayurveda?
What were KRM Ayurveda's latest quarterly results?
KRM Ayurveda Ltd reported revenue of ₹32.3 Cr and net profit of ₹9.1 Cr for the Jun 2026 quarter. Revenue rose 31.0% and profit rose 124.2% compared with a year earlier. Earnings per share were ₹4.27.
The operating margin was 37.2%, 12.0 percentage points higher than a year earlier (as of 20 November 2026).
What is KRM Ayurveda's market cap?
KRM Ayurveda Ltd's market capitalisation is ₹469 Cr at a share price of ₹220.35. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 20 November 2026).
How is KRM Ayurveda performing?
KRM Ayurveda Ltd's share price is in an uptrend that has just slipped below its 200-day average. In its latest quarter, revenue rose 31.0% and profit rose 124.2% compared with a year earlier.
Over the past 13 weeks it has done worse than the NIFTY 500, for 5 weeks running (as of 20 November 2026).
Will KRM Ayurveda's share price go up?
This page does not forecast KRM Ayurveda Ltd's share price. What it shows instead: the share price is ₹220.35, and it has been rising for 37 weeks. Its P/E of 23.3× is higher than 0% of its own last 1 years (as of 20 November 2026).
Who owns KRM Ayurveda?
Promoters own 69.3% of KRM Ayurveda Ltd, foreign institutions 1.5%, domestic institutions 2.7% and the public 26.5% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 20 November 2026).
Where is KRM Ayurveda in its business cycle?
KRM Ayurveda Ltd's FY26 operating margin was 29.4%, against a 4-year range of 11.9% to 29.4%. The latest quarter was 37.2%, above the top of its own yearly range in the latest quarter, so margins are at a high and the story depends on them staying there.
Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 20 November 2026).
What could break the KRM Ayurveda story?
The main question: profits are rising, but only 9% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch.
On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 20 November 2026).
Is KRM Ayurveda a stock worth studying right now?
What the numbers show: KRM Ayurveda Ltd's results are improving, while its P/E is near the low end of its own history over 10 months, higher than only 0% of past readings. The main open question: whether the cash starts to follow the profit.
Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 20 November 2026).
Where do these numbers come from?
Sector Alpha, written by code from the published numbers. Data as of 20 November 2026.
Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.
See the plain-text version of this page.
More lists
Every Sector Alpha list, grouped
Stock screens
Market lists
Themes
Sectors
X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.